Nonimmune Complications After Transplantation

Pediatric Clinics of North America

Volumn 57, Issue 2, 2010, Pages 505-521

  Choquette, Monique ^a   Goebel, Jens W ^b   Campbell, Kathleen M ^b  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Immunosuppression complications; Long term outcome; Pediatric transplantation; Posttransplant renal dysfunction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCINEURIN INHIBITOR; CALCITRIOL; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; CYTOCHROME P450 3A4; DAPSONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA1; VALGANCICLOVIR; VITAMIN D;

ANEMIA; BLOOD DYSCRASIA; BONE DISEASE; BONE MARROW SUPPRESSION; CARDIOVASCULAR DISEASE; CUSHINGOID SYNDROME; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; DNA SYNTHESIS INHIBITION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GINGIVA HYPERPLASIA; GRAFT REJECTION; HAIR LOSS; HEART LEFT VENTRICLE WALL; HEART VENTRICLE HYPERTROPHY; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HIRSUTISM; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY DYSFUNCTION; LEUKOPENIA; METABOLIC DISORDER; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; POSTTRANSPLANTATION COMPLICATION; PREVALENCE; PRIMARY MEDICAL CARE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; PURE RED CELL ANEMIA; REVIEW; RISK FACTOR; SIDE EFFECT; SPONTANEOUS ABORTION; STEROID THERAPY; THROMBOCYTOPENIA; WEIGHT GAIN;

BONE DISEASES; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; DIABETES MELLITUS; HEMATOLOGIC DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; ORGAN TRANSPLANTATION; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS;

EID: 77951004937     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2010.01.008     Document Type: Review

References (77)

1. Ojo A.O., Held P.J., Port F.K., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003, 349:931.
2. Harambat J., Ranchin B., Dubourg L., et al. Renal function in pediatric liver transplantation: a long-term follow-up study. Transplantation 2008, 86:1028.
3. Campbell K.M., Yazigi N., Ryckman F.C., et al. High prevalence of renal dysfunction in long-term survivors after pediatric liver transplantation. J Pediatr 2006, 148:475.
4. Bharat W., Manlhiot C., McCrindle B.W., et al. The profile of renal function over time in a cohort of pediatric heart transplant recipients. Pediatr Transplant 2009, 13:111.
5. Lee C.K., Christensen L.L., Magee J.C., et al. Pre-transplant risk factors for chronic renal dysfunction after pediatric heart transplantation: a 10-year national cohort study. J Heart Lung Transplant 2007, 26:458.
6. Sachdeva R., Blaszak R.T., Ainley K.A., et al. Determinants of renal function in pediatric heart transplant recipients: long-term follow-up study. J Heart Lung Transplant 2007, 26:108.
7. Watson M.J., Venick R.S., Kaldas F., et al. Renal function impacts outcomes after intestinal transplantation. Transplantation 2008, 86:117.
8. Hmiel S.P., Beck A.M., de la Morena M.T., et al. Progressive chronic kidney disease after pediatric lung transplantation. Am J Transplant 2005, 5:1739.
9. Hocker B., Tonshoff B. Treatment strategies to minimize or prevent chronic allograft dysfunction in pediatric renal transplant recipients: an overview. Paediatr Drugs 2009, 11:381.
10. Ishikawa T., Tsuji A., Inui K., et al. The genetic polymorphism of drug transporters: functional analysis approaches. Pharmacogenomics 2004, 5:67.
11. Zhang Y., Benet L.Z. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001, 40:159.
12. Roy J.N., Barama A., Poirier C., et al. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics 2006, 16:659.
13. Wei-lin W., Jing J., Shu-sen Z., et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl 2006, 12:775.
14. Hauser I.A., Schaeffeler E., Gauer S., et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005, 16:1501.
15. Hebert M.F., Dowling A.L., Gierwatowski C., et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 2003, 13:661.
16. Khanna A.K., Cairns V.R., Becker C.G., et al. Transforming growth factor (TGF)-beta mimics and anti-TGF-beta antibody abrogates the in vivo effects of cyclosporine: demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine. Transplantation 1999, 67:882.
17. Khanna A.K., Hosenpud J.S., Plummer M.S., et al. Analysis of transforming growth factor-beta and profibrogenic molecules in a rat cardiac allograft model treated with cyclosporine. Transplantation 2002, 73:1543.
18. van de Wetering J., Weimar C.H., Balk A.H., et al. The impact of transforming growth factor-beta1 gene polymorphism on end-stage renal failure after heart transplantation. Transplantation 2006, 82:1744.
19. Siekierka-Harreis M., Kuhr N., Willers R., et al. Impact of genetic polymorphisms of the renin-angiotensin system and of non-genetic factors on kidney transplant function-a single-center experience. Clin Transplant 2009, 23:606.
20. Neuberger J.M., Mamelok R.D., Neuhaus P., et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant 2009, 9:327.
21. Wilson C.H., Brook N.R., Gok M.A., et al. Randomized clinical trial of daclizumab induction and delayed introduction of tacrolimus for recipients of non-heart-beating kidney transplants. Br J Surg 2005, 92:681.
22. Boyer O., Le Bidois J., Dechaux M., et al. Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. Transplantation 2005, 79:1405.
23. Evans H.M., McKiernan P.J., Kelly D.A. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation. Transplantation 2005, 79:1575.
24. Henne T., Latta K., Strehlau J., et al. Mycophenolate mofetil-induced reversal of glomerular filtration loss in children with chronic allograft nephropathy. Transplantation 2003, 76:1326.
25. Hocker B., Feneberg R., Kopf S., et al. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity. Pediatr Transplant 2006, 10:593.
26. Balfour I.C., Srun S.W., Wood E.G., et al. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients. J Heart Lung Transplant 2006, 25:518.
27. Shihab F.S., Bennett W.M., Yi H., et al. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 2004, 65:1262.
28. Pallet N., Thervet E., Legendre C., et al. Sirolimus early graft nephrotoxicity: clinical and experimental data. Curr Drug Saf 2006, 1:179.
29. Tonshoff B., Hocker B. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Pediatr Transplant 2006, 10:721.
30. Roos J.F., Doust J., Tett S.E., et al. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children-a meta-analysis. Clin Biochem 2007, 40:383.
31. Biancofiore G., Pucci L., Cerutti E., et al. Cystatin C as a marker of renal function immediately after liver transplantation. Liver Transpl 2006, 12:285.
32. Dello Strologo L., Parisi F., Legato A., et al. Long-term renal function in heart transplant children on cyclosporine treatment. Pediatr Nephrol 2006, 21:561.
33. Letavernier E., Legendre C. mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev (Orlando) 2008, 22:125.
34. Mells G., Neuberger J. Reducing the risks of cardiovascular disease in liver allograft recipients. Transplantation 2007, 83:1141.
35. Petroski R.A., Grady K.L., Rodgers S., et al. Quality of life in adult survivors greater than 10 years after pediatric heart transplantation. J Heart Lung Transplant 2009, 28:661.
36. Dharnidharka V.R., Araya C.E., Benfield M.R. Organ toxicities. Pediatric solid organ transplantation 2007, 124-139. Blackwell Publishing Ltd, Oxford (UK). 2nd edition. R.N. Fine, S.A. Webber, W.E. Harmon (Eds.).
37. Baluarte H.J., Gruskin A.B., Ingelfinger J.R., et al. Analysis of hypertension in children post renal transplantation-a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Nephrol 1994, 8:570.
38. Jain A., Mazariegos G., Kashyap R., et al. Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. Transplantation 2000, 70:617.
39. Nakata Y., Yoshibayashi M., Yonemura T., et al. Tacrolimus and myocardial hypertrophy. Transplantation 2000, 69:1960.
40. Shalev A., Nir A., Granot E. Cardiac function in children post-orthotopic liver transplantation: echocardiographic parameters and biochemical markers of subclinical cardiovascular damage. Pediatr Transplant 2005, 9:718.
41. Burroughs T.E., Swindle J.P., Salvalaggio P.R., et al. Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients. Transplantation 2009, 88:367.
42. Simmonds J., Dewar C., Dawkins H., et al. Tacrolimus in pediatric heart transplantation: ameliorated side effects in the steroid-free, statin era. Clin Transplant 2009, 23:415.
43. Hathout E., Alonso E., Anand R., et al. Post-transplant diabetes mellitus in pediatric liver transplantation. Pediatr Transplant 2009, 13:599.
44. Gomes M.B., Cobas R.A. Post-transplant diabetes mellitus. Diabetol Metab Syndr 2009, 1:14.
45. Heisel O., Heisel R., Balshaw R., et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004, 4:583.
46. Greenspan L.C., Gitelman S.E., Leung M.A., et al. Increased incidence in post-transplant diabetes mellitus in children: a case-control analysis. Pediatr Nephrol 2002, 17:1.
47. Singh T.P., Naftel D.C., Webber S., et al. Hyperlipidemia in children after heart transplantation. J Heart Lung Transplant 2006, 25:1199.
48. Trompeter R., Filler G., Webb N.J., et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002, 17:141.
49. Vincenti F., Jensik S.C., Filo R.S., et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002, 73:775.
50. Ligtenberg G., Hene R.J., Blankestijn P.J., et al. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001, 12:368.
51. Hanevold C.D., Ho P.L., Talley L., et al. Obesity and renal transplant outcome: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatrics 2005, 115:352.
52. Rossano J.W., Grenier M.A., Dreyer W.J., et al. Effect of body mass index on outcome in pediatric heart transplant patients. J Heart Lung Transplant 2007, 26:718.
53. Ng V.L., Fecteau A., Shepherd R., et al. Outcomes of 5-year survivors of pediatric liver transplantation: report on 461 children from a North American multicenter registry. Pediatrics 2008, 122:e1128.
54. Curtis J.J., Galla J.H., Woodford S.Y., et al. Effect of alternate-day prednisone on plasma lipids in renal transplant recipients. Kidney Int 1982, 22:42.
55. Hricik D.E., Knauss T.C., Bodziak K.A., et al. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 2003, 76:938.
56. Li L., Chang A., Naesens M., et al. Steroid-free immunosuppression since 1999: 129 pediatric renal transplants with sustained graft and patient benefits. Am J Transplant 2009, 9:1362.
57. Khosroshahi H.T., Asghari A., Estakhr R., et al. Effects of azathioprine and mycophenolate mofetil-immunosuppressive regimens on the erythropoietic system of renal transplant recipients. Transplant Proc 2006, 38:2077.
58. Maheshwari A., Mishra R., Thuluvath P.J. Post-liver-transplant anemia: etiology and management. Liver Transpl 2004, 10:165.
59. Gupta P., Kaufman S., Fishbein T.M. Sirolimus for solid organ transplantation in children. Pediatr Transplant 2005, 9:269.
60. Danziger-Isakov L., Mark Baillie G. Hematologic complications of anti-CMV therapy in solid organ transplant recipients. Clin Transplant 2009, 23:295.
61. Erol I., Alehan F., Ozcay F., et al. Neurological complications of liver transplantation in pediatric patients: a single center experience. Pediatr Transplant 2007, 11:152.
62. Cilio M.R., Danhaive O., Gadisseux J.F., et al. Unusual cyclosporin related neurological complications in recipients of liver transplants. Arch Dis Child 1993, 68:405.
63. Bohlin A.B., Berg U., Englund M., et al. Central nervous system complications in children treated with ciclosporin after renal transplantation. Child Nephrol Urol 1990, 10:225.
64. Bartynski W.S., Tan H.P., Boardman J.F., et al. Posterior reversible encephalopathy syndrome after solid organ transplantation. AJNR Am J Neuroradiol 2008, 29:924.
65. Draper H.M. Depressive disorder associated with mycophenolate mofetil. Pharmacotherapy 2008, 28:136.
66. Neff R.T., Hurst F.P., Falta E.M., et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 2008, 86:1474.
67. Goksen D., Darcan S., Kara P., et al. Bone mineral density in pediatric and adolescent renal transplant patients: how to evaluate. Pediatr Transplant 2005, 9:464.
68. Saland J.M. Osseous complications of pediatric transplantation. Pediatr Transplant 2004, 8:400.
69. Valta H., Jalanko H., Holmberg C., et al. Impaired bone health in adolescents after liver transplantation. Am J Transplant 2008, 8:150.
70. Guthery S.L., Pohl J.F., Bucuvalas J.C., et al. Bone mineral density in long-term survivors following pediatric liver transplantation. Liver Transpl 2003, 9:365.
71. Sachdeva R., Soora R., Bryant J.C., et al. Bone mineral status in pediatric heart transplant recipients: a retrospective observational study of an " at risk" cohort. Pediatr Transplant 2009, [Epub ahead of print].
72. El-Husseini A.A., El-Agroudy A.E., El-Sayed M.F., et al. Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatr Transplant 2004, 8:357.
73. Walker R.G., Cottrell S., Sharp K., et al. Conversion of cyclosporine to tacrolimus in stable renal allograft recipients: quantification of effects on the severity of gingival enlargement and hirsutism and patient-reported outcomes. Nephrology (Carlton) 2007, 12:607.
74. Shiboski C.H., Krishnan S., Besten P.D., et al. Gingival enlargement in pediatric organ transplant recipients in relation to tacrolimus-based immunosuppressive regimens. Pediatr Dent 2009, 31:38.
75. Wielgos M., Pietrzak B., Bobrowska K., et al. Pregnancy after organ transplantation. Neuro Endocrinol Lett 2009, 30:6.
76. Tsimaratos M., Viard L., Kreitmann B., et al. Kidney function in cyclosporine-treated paediatric pulmonary transplant recipients. Transplantation 2000, 69:2055.
77. Herzog D., Martin S., Turpin S., et al. Normal glomerular filtration rate in long-term follow-up of children after orthotopic liver transplantation. Transplantation 2006, 81:672.